IRIS Accounts Production v24.3.2.46 08059569 director 1.6.23 31.5.24 31.5.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh080595692023-05-31080595692024-05-31080595692023-06-012024-05-31080595692022-05-31080595692022-06-012023-05-31080595692023-05-3108059569ns15:EnglandWales2023-06-012024-05-3108059569ns14:PoundSterling2023-06-012024-05-3108059569ns10:Director12023-06-012024-05-3108059569ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3108059569ns10:SmallEntities2023-06-012024-05-3108059569ns10:AuditExempt-NoAccountantsReport2023-06-012024-05-3108059569ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3108059569ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3108059569ns10:FullAccounts2023-06-012024-05-3108059569ns10:RegisteredOffice2023-06-012024-05-3108059569ns5:CurrentFinancialInstruments2024-05-3108059569ns5:CurrentFinancialInstruments2023-05-3108059569ns5:ShareCapital2024-05-3108059569ns5:ShareCapital2023-05-3108059569ns5:RetainedEarningsAccumulatedLosses2024-05-3108059569ns5:RetainedEarningsAccumulatedLosses2023-05-3108059569ns5:PlantMachinery2023-06-012024-05-3108059569ns5:PlantMachinery2023-05-3108059569ns5:PlantMachinery2024-05-3108059569ns5:PlantMachinery2023-05-3108059569ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-05-3108059569ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-05-3108059569ns5:RetainedEarningsAccumulatedLosses2023-05-3108059569ns5:RetainedEarningsAccumulatedLosses2023-06-012024-05-31
REGISTERED NUMBER: 08059569 (England and Wales)















Financial Statements for the Year Ended 31st May 2024

for

Delta Pharmaceutics Limited

Delta Pharmaceutics Limited (Registered number: 08059569)

Contents of the Financial Statements
for the year ended 31st May 2024










Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


Delta Pharmaceutics Limited

Company Information
for the year ended 31st May 2024







DIRECTOR: D Douroumis





REGISTERED OFFICE: 1 - 3 Manor Road
Chatham
Kent
ME4 6AE





REGISTERED NUMBER: 08059569 (England and Wales)





ACCOUNTANTS: Beak Kemmenoe
Chartered Accountants
1-3 Manor Road
Chatham
Kent
ME4 6AE

Delta Pharmaceutics Limited (Registered number: 08059569)

Statement of Financial Position
31st May 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 7,940 9,969

CURRENT ASSETS
Debtors 5 218,120 46,744
Cash at bank 87,638 195,396
305,758 242,140
CREDITORS
Amounts falling due within one year 6 166,047 149,735
NET CURRENT ASSETS 139,711 92,405
TOTAL ASSETS LESS CURRENT
LIABILITIES

147,651

102,374

PROVISIONS FOR LIABILITIES 1,985 2,512
NET ASSETS 145,666 99,862

CAPITAL AND RESERVES
Called up share capital 7 30,200 200
Retained earnings 8 115,466 99,662
SHAREHOLDERS' FUNDS 145,666 99,862

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st May 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Delta Pharmaceutics Limited (Registered number: 08059569)

Statement of Financial Position - continued
31st May 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 27th February 2025 and were signed by:





D Douroumis - Director


Delta Pharmaceutics Limited (Registered number: 08059569)

Notes to the Financial Statements
for the year ended 31st May 2024


1. STATUTORY INFORMATION

Delta Pharmaceutics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance

Research grants
Research grants in relation to revenue are recognised in income on a systematic basis over the periods in which the entity recognises the related costs for which the grant is intended to compensate.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

Delta Pharmaceutics Limited (Registered number: 08059569)

Notes to the Financial Statements - continued
for the year ended 31st May 2024


4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1st June 2023 18,582
Additions 618
At 31st May 2024 19,200
DEPRECIATION
At 1st June 2023 8,613
Charge for year 2,647
At 31st May 2024 11,260
NET BOOK VALUE
At 31st May 2024 7,940
At 31st May 2023 9,969

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 31,400 38,744
Other debtors and prepayments 186,720 8,000
218,120 46,744

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Corporation tax 8,126 456
Social security and other taxes 6,962 8,312
Other creditors and accruals 150,959 140,967
166,047 149,735

Delta Pharmaceutics Limited (Registered number: 08059569)

Notes to the Financial Statements - continued
for the year ended 31st May 2024


7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Nominal 2024 2023
Number: Class: value: £ £
20,070 Ordinary £1 20,070 70
10,035 A Ordinary £1 10,035 35
65 B Ordinary £1 65 65
10 C Ordinary £1 10 10
10 D Ordinary £1 10 10
10 E Ordinary £1 10 10
30,200 200


During the year the company issued 20,000 Ordinary shares and 10,000 A Ordinary shares at par value.

8. RESERVES
Retained
earnings
£   

At 1st June 2023 99,662
Profit for the year 15,804
At 31st May 2024 115,466

9. ULTIMATE CONTROLLING PARTY

The controlling party is D Douroumis.